Harrow, Inc. (HROW)
NASDAQ: HROW · Real-Time Price · USD
24.76
-0.31 (-1.24%)
Apr 25, 2025, 11:28 AM EDT - Market open
Harrow Revenue
In the year 2024, Harrow had annual revenue of $199.61M with 53.32% growth. Harrow had revenue of $66.83M in the quarter ending December 31, 2024, with 83.83% growth.
Revenue (ttm)
$199.61M
Revenue Growth
+53.32%
P/S Ratio
4.48
Revenue / Employee
$522,550
Employees
382
Market Cap
882.80M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 199.61M | 69.42M | 53.32% |
Dec 31, 2023 | 130.19M | 41.60M | 46.95% |
Dec 31, 2022 | 88.60M | 16.12M | 22.24% |
Dec 31, 2021 | 72.48M | 23.61M | 48.30% |
Dec 31, 2020 | 48.87M | -2.29M | -4.48% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.90B |
HROW News
- 1 day ago - NORDIC GROUP B.V. THROUGH ITS SUBSIDIARY NORDIC PHARMA, INC. - PRNewsWire
- 15 days ago - Harrow Expands VEVYE® Access for All Program to ImprimisRx's Klarity-C Patients - Business Wire
- 26 days ago - Harrow: When Cheaper Doesn't Mean Attractive (Rating Upgrade) - Seeking Alpha
- 27 days ago - Harrow, Inc. (HROW) Q4 2024 Earnings Conference Call - Seeking Alpha
- 27 days ago - Harrow Inc.: Roll The Dice For Strong Upside Prospects As Earnings Ramp - Seeking Alpha
- 4 weeks ago - Harrow Announces Fourth-Quarter and Year-End 2024 Audited Financial Results - Business Wire
- 4 weeks ago - Harrow To Report Fourth Quarter and Audited Year-End 2024 Financial Results After Market Close on March 27, 2025 - Business Wire
- 4 weeks ago - Harrow Announces Transitional Pass-Through Reimbursement Status for TRIESENCE® (Triamcinolone Acetonide Injectable Suspension) 40 mg/mL - Business Wire